Display options
Cite
Wang SY, Shih YH, Shieh TM, et al. Proteasome Inhibitors Interrupt the Activation of Non-Canonical NF-κB Signaling Pathway and Induce Cell Apoptosis in Cytarabine-Resistant HL60 Cells. Int J Mol Sci. 2021;23(1)doi: 10.3390/ijms23010361.
Wang, S. Y., Shih, Y. H., Shieh, T. M., & Tseng, Y. H. (2021). Proteasome Inhibitors Interrupt the Activation of Non-Canonical NF-κB Signaling Pathway and Induce Cell Apoptosis in Cytarabine-Resistant HL60 Cells. International journal of molecular sciences, 23(1), . https://doi.org/10.3390/ijms23010361
Wang, Shuo-Yu, et al. "Proteasome Inhibitors Interrupt the Activation of Non-Canonical NF-κB Signaling Pathway and Induce Cell Apoptosis in Cytarabine-Resistant HL60 Cells." International journal of molecular sciences vol. 23,1 (2021). doi: https://doi.org/10.3390/ijms23010361
Wang SY, Shih YH, Shieh TM, Tseng YH. Proteasome Inhibitors Interrupt the Activation of Non-Canonical NF-κB Signaling Pathway and Induce Cell Apoptosis in Cytarabine-Resistant HL60 Cells. Int J Mol Sci. 2021 Dec 29;23(1). doi: 10.3390/ijms23010361. PMID: 35008789; PMCID: PMC8745175.
Copy Download .nbib Format: NLM
Share it on

Int J Mol Sci. 2021 Dec 29;23(1). doi: 10.3390/ijms23010361.

Proteasome Inhibitors Interrupt the Activation of Non-Canonical NF-κB Signaling Pathway and Induce Cell Apoptosis in Cytarabine-Resistant HL60 Cells.

International journal of molecular sciences

Shuo-Yu Wang, Yin-Hwa Shih, Tzong-Ming Shieh, Yu-Hsin Tseng

Affiliations

  1. Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan.
  2. Department of Pediatrics, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
  3. Department of Healthcare Administration, Asia University, Taichung 41354, Taiwan.
  4. School of Dentistry, China Medical University, Taichung 40402, Taiwan.
  5. Department of Dental Hygiene, China Medical University, Taichung 40402, Taiwan.

PMID: 35008789 PMCID: PMC8745175 DOI: 10.3390/ijms23010361

Abstract

Over half of older patients with acute myeloid leukemia (AML) do not respond to cytotoxic chemotherapy, and most responders relapse because of drug resistance. Cytarabine is the main drug used for the treatment of AML. Intensive treatment with high-dose cytarabine can increase the overall survival rate and reduce the relapse rate, but it also increases the likelihood of drug-related side effects. To optimize cytarabine treatment, understanding the mechanism underlying cytarabine resistance in leukemia is necessary. In this study, the gene expression profiles of parental HL60 cells and cytarabine-resistant HL60 (R-HL60) cells were compared through gene expression arrays. Then, the differential gene expression between parental HL60 and R-HL60 cells was measured using KEGG software. The expression of numerous genes associated with the nuclear factor κB (NF-κB) signaling pathway changed during the development of cytarabine resistance. Proteasome inhibitors inhibited the activity of non-canonical NF-κB signaling pathway and induced the apoptosis of R-HL60 cells. The study results support the application and possible mechanism of proteasome inhibitors in patients with relapsed or refractory leukemia.

Keywords: NF-κB; cytarabine-resistant HL60; leukemia; proteasome inhibitors

References

  1. Cancers (Basel). 2021 Feb 25;13(5): - PubMed
  2. Leukemia. 2017 May;31(5):1187-1195 - PubMed
  3. J Clin Invest. 2012 Mar;122(3):935-47 - PubMed
  4. Adv Exp Med Biol. 2008;615:223-50 - PubMed
  5. Pharmacogenomics. 2015 Jul;16(8):877-90 - PubMed
  6. Mol Cancer. 2013 Aug 02;12:86 - PubMed
  7. Biomed Pharmacother. 2020 Oct;130:110569 - PubMed
  8. Mol Cancer. 2012 Sep 20;11:71 - PubMed
  9. Curr Oncol Rep. 2020 Jun 8;22(7):66 - PubMed
  10. Biomedicines. 2017 May 31;5(2): - PubMed
  11. Curr Opin Hematol. 2010 Mar;17(2):79-84 - PubMed
  12. J Lipid Res. 2019 Jun;60(6):1078-1086 - PubMed
  13. J Biol Chem. 2004 Aug 13;279(33):34323-31 - PubMed
  14. Biochem Pharmacol. 2000 Oct 15;60(8):1143-51 - PubMed
  15. J Immunol. 2012 Nov 1;189(9):4437-43 - PubMed
  16. Nature. 2008 Oct 30;455(7217):1205-9 - PubMed
  17. Biomed Pharmacother. 2018 Aug;104:729-737 - PubMed
  18. Cancer Biol Ther. 2005 Jan;4(1):77-82 - PubMed
  19. Exp Hematol Oncol. 2013 Aug 06;2:20 - PubMed
  20. Pharmacol Rev. 2019 Apr;71(2):170-197 - PubMed
  21. Leuk Res. 2002 Jul;26(7):621-9 - PubMed
  22. Cancer Discov. 2017 Jul;7(7):670-672 - PubMed
  23. Curr Drug Targets. 2015;16(4):284-94 - PubMed
  24. Int J Oncol. 2011 Apr;38(4):911-9 - PubMed
  25. Cell Commun Signal. 2010 Dec 22;8:31 - PubMed
  26. Biol Pharm Bull. 2007 Nov;30(11):2069-74 - PubMed
  27. Arch Med Res. 2020 Oct;51(7):636-644 - PubMed
  28. Drug Resist Updat. 2020 Jan;48:100663 - PubMed
  29. Cells. 2020 Apr 30;9(5): - PubMed
  30. Nat Immunol. 2011 Jul 19;12(8):695-708 - PubMed
  31. Cancer Sci. 2019 Dec;110(12):3802-3810 - PubMed
  32. Int J Mol Med. 2019 Feb;43(2):1011-1020 - PubMed
  33. Leukemia. 2007 Jan;21(1):84-92 - PubMed
  34. Am J Physiol Lung Cell Mol Physiol. 2006 Apr;290(4):L622-L645 - PubMed
  35. Sci Rep. 2016 Dec 08;6:38553 - PubMed
  36. Wiley Interdiscip Rev Syst Biol Med. 2016 May;8(3):227-41 - PubMed
  37. J Cell Physiol. 2019 Aug;234(8):12404-12414 - PubMed
  38. Phytother Res. 2019 Apr;33(4):1199-1207 - PubMed
  39. BMC Cancer. 2018 Apr 25;18(1):466 - PubMed
  40. Exp Hematol. 2010 Oct;38(10):908-921.e1 - PubMed
  41. Eur J Biochem. 2001 Mar;268(5):1508-15 - PubMed
  42. Blood. 2019 Jan 3;133(1):7-17 - PubMed
  43. Cancer Res. 2008 Apr 1;68(7):2349-57 - PubMed
  44. Cell Death Dis. 2021 Mar 3;12(3):231 - PubMed
  45. Transl Res. 2018 Aug;198:1-16 - PubMed
  46. J Dent Res. 2021 Jan;100(1):10-20 - PubMed
  47. Pharmaceuticals (Basel). 2021 Aug 12;14(8): - PubMed
  48. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3925-9 - PubMed
  49. Signal Transduct Target Ther. 2020 Sep 21;5(1):209 - PubMed
  50. Leukemia. 2009 Jun;23(6):1098-105 - PubMed
  51. Biochem Pharmacol. 2010 Mar 1;79(5):706-14 - PubMed
  52. J Cell Commun Signal. 2011 Jun;5(2):101-10 - PubMed
  53. Haematologica. 2018 Aug;103(8):1269-1277 - PubMed
  54. Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2220-2225 - PubMed
  55. Cell Death Dis. 2019 May 17;10(6):390 - PubMed
  56. Nat Rev Immunol. 2012 Nov;12(11):774-85 - PubMed
  57. Oncotarget. 2015 Mar 20;6(8):5490-500 - PubMed
  58. Mol Med Rep. 2020 Jan;21(1):329-337 - PubMed
  59. Molecules. 2017 Mar 21;22(3): - PubMed
  60. Cancers (Basel). 2020 Jan 02;12(1): - PubMed
  61. Clin Cancer Res. 2019 Jul 15;25(14):4231-4237 - PubMed
  62. Cancer Cell. 2010 Jun 15;17(6):597-608 - PubMed
  63. N Engl J Med. 2020 Aug 13;383(7):617-629 - PubMed

Publication Types

Grant support